Sie suchten nach: for venous thromboembolic event (Englisch - Maltesisch)

venous thromboembolic event g
avveniment tromboemboliku fil- vini ġ

thromboembolic event
avveniment trombo- embolitiku

venous thromboembolic eventd
avveniment tromboemboliku venużd

venous thromboembolic events,
trombożi tal-vini profondi u

5 venous thromboembolic events:
każijiet ta ’ trombo- emboliżmu fil- vini:

venous thromboembolic events (vte)
avvenimenti venużi avvenimenti tromboemboliċi (vte)

venous and arterial thromboembolic events
avvenimenti tromboemboliċi fil-vini u fl-arterji

venous thromboembolic events have rarely been reported.
avvenimenti tromboemboliċi venużi kienu rrappurtati b’mod rari.

other venous thromboembolic events could also occur.
jistgħu jseħħu wkoll tipi oħra ta’ każijiet ta’ trombo-emboliżmu fil-vini.

thromboembolic events
avvenimenti tromboembolitiċi

vascular disorders venous thromboembolic events have rarely been reported.
Ġrajjiet tromboemboliċi kienu rarament irrapportati.

grade 4 venous thromboembolic events (including pulmonary embolism)
episodji tromboembolitiċi fil-vini tal-grad 4 (inkluż emboliżmu pulmonari)

venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism^
avvenimenti tromboemboliċi venużi, trombożi tal-vini profondi u emboliżmu pulmonari b’mod predominanti^,

venous thromboembolic events include deep venous thrombosis, pulmonary embolism and thrombophlebitis.
avvenimenti trombo- embolitiċi venużi jinkludu trombożi fil- vini l- kbar, emboliżmu fil- pulmun u tromboflebite.

prevention of venous thromboembolic events (vte) in patients undergoing hip fracture ct
l- inċidenza ta ’ vte sintomatika, inkluż pe ma kienx differenti b’ mod sinifikanti bejn il- gruppi ta ’ trattament.

prevention of venous thromboembolic events (vte) in patients undergoing abdominal surgery ici
fsada maġġuri, kollha f’ siti kirurġiċi u mhux fatali, kienu osservati fi 8 pazjenti (2. 4%) trattati b’ fondaparinux 2. 5 mg ipparagunati ma ’ 2 (0. 6%) bil- plaċebo.

the materials will address the risks concerning arterial / venous thromboembolic events and cardiorespiratory disorders.
il-materjali se jindirizzaw ir-riskji li għandhom x’jaqsmu ma’ avvenimenti tromboemboliċi arterjali / venużi u disturbi kardjorespiratorji.

serious venous thromboembolic events may occur rarely (less than 1 case per 1,000 patients).
avvenimenti tromboemboliċi fil-vini serji jistgħu jseħħu rarament (anqas minn każ wieħed kull 1 000 pazjent).

raloxifene is associated with an increased risk for venous thromboembolic events that is similar to the reported risk associated with current use of hormone replacement therapy.
raloxifene huwa assoċjat ma’ riskju miżjud ta’ avvenimenti tromboembolitiċi fil-vini, li huwa simili għal dak irrappurtat li hu assoċjat ma’ l-użu kurrenti tat-terapija bl-ormoni, bħala sostitut.

in clinical studies with pazopanib, venous thromboembolic events including venous thrombosis and fatal pulmonary embolus have occurred.
fi studji kliniċi b’pazopanib, seħħew avvenimenti tromboemboliċi venużi inkluż trombożi fil-vini u embolu fatali fil-pulmun.